补阳还五汤治疗中风后遗症的循证评价:PRISMA系统综述与Meta分析
Meta分析显示,在常规治疗基础上加用补阳还五汤可显著提高临床有效率(RR=1.24, 95%CI: 1.20-1.29, p<0.00001)、降低NIHSS评分(MD=-5.42, 95%CI: -5.87至-4.97, p<0.00001)并提高FMA评分(MD=17.28, 95%CI: 15.12-19.45, p<0.00001),未报告不良事件,证据质量多为中等。
要点
- 补阳还五汤联合常规治疗可提高中风后遗症患者临床有效率。
- 联合治疗可降低NIHSS评分、提高FMA评分,促进神经与运动功能康复。
- 纳入研究未报告不良事件,但长期安全性需高质量试验验证。
核心结论
- 在常规治疗基础上加用补阳还五汤可显著改善中风后遗症患者的临床有效率并促进神经康复。
- 纳入研究未报告与联合治疗相关的不良事件,但长期有效性与安全性仍需高质量试验评估。
研究设计与样本
- 遵循PRISMA指南的系统综述与Meta分析,检索5个常用电子数据库至2022年5月20日。
- 采用Cochrane偏倚风险工具评估方法学质量,Review Manager 5.4分析数据,GRADE系统评价证据质量。
主要发现
- 与单用常规治疗相比,加用补阳还五汤显著提高临床有效率(RR=1.24, 95%CI: 1.20-1.29, p<0.00001)。
- 加用补阳还五汤显著降低NIHSS评分(MD=-5.42, 95%CI: -5.87至-4.97, p<0.00001)。
- 加用补阳还五汤显著提高FMA评分(MD=17.28, 95%CI: 15.12-19.45, p<0.00001)。
- 纳入研究未报告不良事件,大多数结果稳健,证据质量多为中等。
关键数值与推荐
- 主要结局为临床有效率(CER),次要结局为NIHSS评分和FMA评分。
- 与常规治疗相比,加用补阳还五汤的CER的RR=1.24(95%CI: 1.20-1.29, p<0.00001)。
- 与常规治疗相比,加用补阳还五汤的NIHSS评分MD=-5.42(95%CI: -5.87至-4.97, p<0.00001)。
- 与常规治疗相比,加用补阳还五汤的FMA评分MD=17.28(95%CI: 15.12-19.45, p<0.00001)。
临床怎么用
- 对中风后遗症患者,可考虑在常规治疗基础上加用补阳还五汤以改善临床有效率和神经功能。
- 补阳还五汤可作为常规治疗的辅助方案用于促进运动功能康复。
- 使用时应关注患者个体情况,并认识到长期疗效与安全性证据尚不充分。
局限性
- 纳入临床试验存在局限性,可能影响结果解释。
- 需要更长期随访的高质量临床试验评估补阳还五汤的长期有效性与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Buyang Huanwu decoction (BYHWD) is a famous traditional Chinese formula that has been widely prescribed for sequelae of stroke in China. However, the efficacy and safety of BYHWD in treating sequelae of stroke have never been systematically evaluated. PURPOSE: To evaluate the effectiveness and safety of BYHWD in the treatment of sequelae of stroke. STUDY DESIGN: A Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA)-compliant systematic review and meta-analysis of randomized clinical trials (RCTs). MATERIALS AND METHODS: A systematic review and meta-analysis was performed in accordance with the PRISMA guidelines. Five common electronic databases were searched for relevant RCTs from their inception until May 20, 2022. The Cochrane risk-of-bias tool was used to evaluate the methodological quality and the risk of bias of the included RCTs. Review Manager 5.4 was used to analyse all the data obtained. The clinical effective rate (CER) was the primary outcome, and National Institutes of Health Stroke Scale (NIHSS) and Fugl-Meyer Assessment (FMA) scores were the secondary outcomes. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system was used to evaluate the quality of evidence for each outcome. RESULTS: Thirty-two clinical studies that recruited 2,527 eligible patients were included in this meta-analysis. The results of the meta-analysis suggested that compared with conventional treatment alone, the addition of BYHWD significantly improved the CER (RR = 1.24, 95% CI: 1.20-1.29, p < 0.00001), decreased the NIHSS score (MD = -5.42, 95% CI: -5.87-4.97, p < 0.00001), and increased the FMA score (MD = 17.28, 95% CI: 15.12-19.45, p < 0.00001). There were no reported adverse events in the included studies. Most results were robust, and the quality of evidence was moderate. CONCLUSION: Our study is the first meta-analysis of RCTs evaluating the effects of BYHWD on sequelae of stroke. The addition of BYHWD to conventional treatment for sequelae of stroke significantly improved the CER and promoted neurological rehabilitation in patients, and there were no reported adverse events associated with this combination therapy. The findings of our study support the use of BYHWD as an adjunct treatment to conventional treatment in this clinical population. However, due to the limitations of the included clinical trials, high-quality clinical trials with longer follow-ups are needed to assess the long-term effectiveness and safety of BYHWD for treating the sequelae of stroke.
引用
- Shao L, She Y, Yong S, et al. An evidence-based evaluation of Buyang Huanwu decoction for the treatment of the sequelae of stroke: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2022. PMID: 35810520. doi:10.1016/j.phymed.2022.154312
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。